The Next Two Weeks in GLP1 Are Huge, Here's Why
http://www.otplinks.com
12 Touko 1h 7min
He Took Retatrutide 40mg and Proved a Point
This episode examines a serious case involving retatrutide, where an individual experienced an overdose due to improper medication administration. We discuss the critical importance of medication safe...
5 Touko 36min
Eli Lilly Earnings Call Recap: Q1 2026
We just got done listening to the quarter one, 2026 Eli Lilly earnings call. There was a lot of information to get into, whether you're interested in retatrutide, eloralintide, or Foundayo, and all of...
30 Huhti 25min
SURVODUTIDE Phase 3 Data: Why Weight Loss Isn't The Whole Story
https://www.otplinks.comA new GLP-1 and glucagon agonist dropped data that was supposed to rival retatrutide, just without the GIP, and on the surface the results look solid. But that is not the real ...
28 Huhti 18min
BPI STOPS TIRZEPATIDE Production, Second Major Pharmacy Out!
Major disruption hits the GLP-1 landscape as another large 503B compounding pharmacy halts production of semaglutide and tirzepatide. In this episode, we unpack what’s driving the FDA’s increased enfo...
23 Huhti 40min
Retatrutide Could Change Everything… But Who Actually Gets It?
ON THE PEN RESOURCES AND LINKS: HTTPS://WWW.OTPLINKS.COMWhat if the most powerful obesity drug ever created ends up being the one you can’t get?That’s the real conversation around retatrutide right no...
21 Huhti 29min
Ozempic Personality With Dr Spencer Nadolsky
This conversation dives headfirst into one of the most controversial and least understood side effects of GLP-1 medications, what many are now calling the “Ozempic personality.” In this candid intervi...
19 Huhti 42min
Foundayo GLP-1 Pill: FDA Needs More Data
Orforglipron (also known as Foundayo) is one of the most promising drugs in the GLP-1 space, notably as only the second oral GLP-1 option for obesity. Unlike injectable treatments, it does not require...
14 Huhti 20min
